Diasorin Italia S P A Pharmaceutical Import Profile — Italy (DGFT 2022–2026)

Name: Diasorin Italia S P A Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Diasorin Italia S P A — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Diasorin Italia S P A

Pharmaceutical Importer · Italy · Medical Devices & Diagnostics Focus · $1.1M Total Trade · DGFT Verified

Diasorin Italia S P A is a pharmaceutical importer based in Italy with a total trade value of $1.1M across 2 products in 1 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Diasorin Italia S P A sources from 1 verified Indian supplier, with Advy Chemical Private Limited accounting for 100.0% of imports.

Diasorin Italia S P A — Import Portfolio & Supplier Network

Diasorin Italia S P A import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Diasorin Italia S P A?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Advy Chemical Private Limited	$200.0K	9	100.0%

Diasorin Italia S P A sources from 1 verified Indian supplier across 6 distinct formulations. The sourcing is highly concentrated — Advy Chemical Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Diagnostic reagents goat anti- human	$100.0K	4
Goat anti- human igg (fc), whole	$50.0K	1
Goat anti- human igg (fc), whole	$50.0K	1
Goat anti- human igg (fc) ,whole serum1000 ML x 1 bottel ( packed ) in 1000 mlbottle	$1	1
Goat anti - human igg (fc), whole	$0	1
Diagnostic reagents goat anti- human	$0	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diagnostic	Medical Devices & Diagnostics	$529.4K	11	1.1%	8
2	Reagent	Medical Devices & Diagnostics	$529.4K	11	1.5%	6

Diasorin Italia S P A imports 2 pharmaceutical products across 1 categories into Italy totaling $1.1M.

Diasorin Italia S P A — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Diasorin Italia S.p.A. is an Italian pharmaceutical company specializing in the manufacture and sale of diagnostic products, including immunodiagnostic and molecular diagnostic testing kits. Established on 7 February 2022, the company is headquartered in Saluggia, Vercelli, Italy. (find-and-update.company-information.service.gov.uk) It operates as a subsidiary of the multinational biotechnology firm DiaSorin S.p.A., which has been a leader in the in vitro diagnostics field since its founding in 1968. Diasorin Italia S.p.A. plays a pivotal role in Italy's pharmaceutical distribution network, focusing on the importation and distribution of diagnostic reagents and related products.

2Distribution Network

While specific details about Diasorin Italia S.p.A.'s warehouse locations and logistics capabilities are not publicly disclosed, the company benefits from the extensive infrastructure of its parent company, DiaSorin S.p.A. DiaSorin operates multiple manufacturing facilities across Europe and the United States, including sites in Italy, Germany, the United Kingdom, and the United States. This global network enables efficient distribution and logistics operations, ensuring timely delivery of products within Italy and to international markets.

3Industry Role

Diasorin Italia S.p.A. functions primarily as a pharmaceutical importer and distributor within Italy's healthcare sector. The company imports finished pharmaceutical formulations, such as diagnostic reagents, from international suppliers, including India. These products are then distributed to various healthcare providers, including hospitals, clinics, and laboratories, facilitating the delivery of diagnostic services across the country. By focusing on the importation and distribution of diagnostic products, Diasorin Italia S.p.A. serves as a critical intermediary in Italy's pharmaceutical supply chain, ensuring the availability of essential diagnostic tools.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Diasorin Italia S P A

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Diasorin Italia S.p.A. demonstrates a high level of sourcing concentration, importing diagnostic and reagent products exclusively from ADVY Chemical Private Limited in India. This single-source dependency may present risks, such as supply chain disruptions due to geopolitical issues, natural disasters, or other unforeseen events affecting the supplier. However, the consistent volume of 22 shipments valued at $1.1 million USD over the period from 2022 to 2026 suggests a stable and reliable relationship between Diasorin Italia S.p.A. and ADVY Chemical Private Limited. The mutual commitment to quality and timely delivery likely contributes to the sustained partnership, mitigating potential risks associated with sourcing from a single supplier.

2Supply Chain Resilience

The resilience of Diasorin Italia S.p.A.'s supply chain is closely tied to the stability and reliability of ADVY Chemical Private Limited. Given the exclusive sourcing arrangement, the company may face challenges if alternative suppliers are not readily available. The lack of publicly available information regarding backup suppliers and formulation diversity indicates a potential vulnerability in the supply chain. Additionally, the exposure to shipping routes and potential regulatory changes in both India and Italy could impact the supply chain's stability. Ensuring compliance with regulatory standards and maintaining open communication channels with ADVY Chemical Private Limited are essential strategies for enhancing supply chain resilience.

Importing Pharmaceuticals into Italy — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Italy

1Regulatory Authority & Framework

In Italy, the Agenzia Italiana del Farmaco (AIFA) is the primary regulatory authority overseeing the pharmaceutical sector. AIFA is responsible for the evaluation, authorization, and monitoring of pharmaceutical products, ensuring they meet the necessary safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Decreto Legislativo 24 aprile 2006, n. 219, which transposes the European Union's Directive 2001/83/EC into Italian law, and the Decreto Legislativo 6 novembre 2007, n. 193, which establishes the regulatory framework for medical devices. For Indian generics to enter the Italian market, they must undergo a marketing authorization process with AIFA, demonstrating compliance with these regulations.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Italy are stringent, necessitating that all imported drugs possess a valid marketing authorization from AIFA. Good Manufacturing Practice (GMP) certification is a critical component of this authorization. Italy recognizes GMP certifications from the European Union, the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Diasorin Italia S.p.A. must ensure their manufacturing facilities are GMP-compliant and hold certifications from these recognized bodies. Additionally, obtaining wholesale distribution authorization is essential for the legal distribution of pharmaceutical products within Italy.

Diasorin Italia S P A — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Diasorin Italia S.p.A.'s focus on importing diagnostic products, particularly diagnostic reagents and related formulations, aligns with the growing demand for advanced diagnostic tools in Italy. The increasing prevalence of chronic diseases, infectious diseases, and the need for personalized medicine drive the demand for accurate and efficient diagnostic solutions. By sourcing high-quality diagnostic products from international suppliers, including India, Diasorin Italia S.p.A. aims to meet this market demand, enhancing healthcare delivery and patient outcomes in Italy.

2Sourcing Profile

Diasorin Italia S.p.A. employs a sourcing strategy that emphasizes quality and reliability, as evidenced by its exclusive partnership with ADVY Chemical Private Limited in India. The company imports finished pharmaceutical formulations, such as diagnostic reagents, ensuring that these products meet the stringent quality standards required by Italian regulatory authorities. India's robust pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a suitable partner for supplying these products.

3Market Positioning

Seller's Guide — How to Become a Supplier to Diasorin Italia S P A

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Italian market by meeting the quality and regulatory standards required by Diasorin Italia S.p.A. The company's exclusive sourcing arrangement with ADVY Chemical Private Limited indicates a potential openness to diversifying its supplier base. Indian exporters can explore this opportunity by ensuring compliance with Italian regulations, obtaining necessary certifications, and demonstrating the quality and reliability of their products.

2Requirements & Qualifications

Indian exporters aiming to supply Diasorin Italia S.p.A. must ensure their manufacturing facilities are compliant with GMP standards recognized by the European Union, WHO, or PIC/S. Obtaining a valid marketing authorization from AIFA is essential, which involves meeting all regulatory requirements, including quality control, stability studies, and labeling in Italian. Additionally, products must comply with serialization mandates to enhance traceability and prevent counterfeiting.

3How to Approach

Frequently Asked Questions — Diasorin Italia S P A

What products does Diasorin Italia S P A import from India?

Diasorin Italia S P A imports 2 pharmaceutical products across 1 categories. Top imports: Diagnostic ($529.4K), Reagent ($529.4K).

Who supplies pharmaceuticals to Diasorin Italia S P A from India?

Diasorin Italia S P A sources from 1 verified Indian suppliers. The primary supplier is Advy Chemical Private Limited (100.0% of imports, $200.0K).

What is Diasorin Italia S P A's total pharmaceutical import value?

Diasorin Italia S P A's total pharmaceutical import value from India is $1.1M, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Diasorin Italia S P A focus on?

Diasorin Italia S P A imports across 1 categories. The largest: Medical Devices & Diagnostics (100.0%).

Get Full Diasorin Italia S P A Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.